Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer (PCa) 35 arising mostly from adenocarcinoma via NE transdifferentiation following androgen 36 deprivation therapy. Mechanisms contributing to both NEPC development and its 37 aggressiveness remain elusive. In light of the fact that hyperchromatic nuclei are a 38 distinguishing histopathological feature of NEPC, we utilized transcriptomic analyses of our 39 patient-derived xenograft (PDX) models, multiple clinical cohorts, and genetically engineered 40 mouse models to identify 36 heterochromatin-related genes that are significantly enriched in 41 NEPC. Longitudinal analysis using our unique, first-in-field PDX model of adenocarcinoma-42 to-NEPC transdifferentiation revealed that, among those 36 heterochromatin-related genes, 
INTRODUCTION 59
Neuroendocrine prostate cancer (NEPC) has become a clinical challenge in the 60 management of castration resistant prostate cancer (CRPC). While de novo cases are rare, 61 NEPC as a special subtype of CRPC (~10-20%) is thought to occur via NE 62 transdifferentiation of prostate adenocarcinomas in response to androgen deprivation 63 treatment (ADT), resisting dependence on AR signaling as an adaptive response. As next-64 generation AR pathway inhibitors (ARPI) such as enzalutamide and abiraterone have made 65 substantial improvements in managing CRPC adenocarcinomas in recent years (1), it is 66 expected that the incidence of NEPC will further increase (2). Unfortunately, the overall 67 median survival of NEPC with small cell feature is less than one year, primarily due to its 68 aggressiveness and limited available treatment options (3). As such, a better understanding 69 of the mechanisms underlying NEPC development remains much needed in order to 70 develop more effective therapeutics. 71
One distinct histopathological feature of NEPC cells is the frequent manifestation of 72 hyperchromatic nuclei with finely dispersed chromatin and inconspicuous nucleoli, a 73 phenomenon known as "salt and pepper" chromatin (3, 4) . This is in contrast to prostatic 74 adenocarcinoma cells, which tend to have enlarged nuclei with prominent nucleoli (3, 4) . This 75 special hematoxylin-staining characteristic suggests a distinct NEPC heterochromatin 76 pattern (5). Heterochromatin is a condensed and transcriptionally inert chromosome 77 conformation, regulated epigenetically by precise and dedicated machineries (6, 7) . Multiple 78 studies have demonstrated that epigenetic regulation is one major mechanism underlying 79
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MATERIAL AND METHODS 125

Patient-derived xenografts and clinical datasets 126
All PDX tumor lines were grafted in NSG mice as previously described (21). This 127 study followed the ethical guidelines stated in Declaration of Helsinki, specimens were 128 obtained from patients with their informed written consent form following a protocol (#H09-129 01628) approved by the Institutional Review Board of the University of British Columbia 130 (UBC). Animal studies under the protocol # A17-0165 were approved by UBC Animal Care 131
and Use Committee. The LTL331 castrated tissues and the NEPC-relapsed LTL331R 132 tissues were harvested at different time points after host castration (22) . Transcriptomic 133 analysis for all PDX tumors, with the exception of the LTL331-331R castration time-series 134 samples, was performed using GE 8x60K microarray, as previously described (21) . 135
Transcriptomic analysis of the LTL331-331R time-series was done using RNA-sequencing 136
data. 137
The clinical cohorts used in this study are as follows: RNA-seq data for the Beltran et 138 al. 2011 cohort (30 adenocarcinomas, 6 NEPCs) was from Weill Medical College of Cornell 139 University (23); RNA-Seq data for the Beltran et al. 2016 (34 CRPC-adenocarcinomas, 15 140 NEPCs) the Grasso et al. 2012 (31 CRPC-adenocarcinomas, 4 NEPCs), and the Kumar et 141 al. 2016 (149 CRPC-adenocarcinomas) cohorts were accessed through the cBioPortal 142 (10, (24) (25) (26) ; microarray data for the Varambally et al. 2015 cohort (6 CRPC-143 adenocarcinomas) was accessed from the Gene Expression Omnibus (GEO) database 144 (GSE3325) (27) . 145
Research. DOI: 10.1158/0008-5472.CAN-17-3677 phenotype induction in V16D cells, cells were starved with phenol-red free RPMI-1640 166 (GIBCO) containing 10% Charcoal-Stripped Serum (CSS) (GIBCO) for 24 hours, then 167 cultured in the same media or with the addition of 10 μM enzalutamide (Haoyuan 168 Chemexpress) for another 14 days (20) . 169
170
Bioinformatics analysis 171
As previously described, Gene Set Enrichment Analysis (GSEA) 172 (http://software.broadinstitute.org/gsea/index.jsp) was used in this study to determine 173 whether a defined set of genes show significant, concordant differences between two 174 biological phenotypes (e.g. PCa adenocarcinoma vs. NEPC) or two sample groups (e.g. shC 175
vs. KD) (28). All GSEA analyses in this study used whole transcriptomic data without 176 expression level cut-off as expression datasets. Normalized values were used for profiling 177 data from PDX tissues, H660 and V16D stable cell lines, and the three NEPC mouse models 178 (GSE90891, GSE92721, GSE86532); raw read numbers was used for RNA-seq data from 179 the Beltran et al. 2011 cohort; pre-ranked gene list based on p-value from lowest to highest 180 was used for the Beltran et al. 2016 cohort (8,10,11,17,21,23 Myc overexpression ( Fig. 1D-1F ) (8, 11, 17) . 235
To further decipher the genes contributing to the heterochromatin feature of NEPC, 236 we analyzed the leading edge genes derived from the GSEA of PDX and clinical NEPC 237 samples ( Fig. 1A-1C ). Since the NEPCs in our PDX collection are all typical neuroendocrine 238 carcinomas without mixed adenocarcinoma tissues, the upregulated genes identified in the 239 NEPC PDXs and validated in the clinical cohorts can be considered heterochromatin 240 signature genes. In addition, three polycomb-group (PcG) genes, EZH2, RBBP4 and RBBP7, 241 are also included in this gene signature as their upregulated expression in NEPC have been 242 previously reported (9,23). They have also been reported to play important roles in 243 heterochromatin formation (7), but are omitted from the GSEA geneset (GO:0000792) 244 containing other PcG members. As such, 36 genes were identified and selected to form a 245 heterochromatin gene panel, which could successfully distinguish NEPC from 246 adenocarcinoma through hierarchical clustering similar to two reported NE score gene 247 panels (Fig. 1G , S1B-S1E) (10, 18) . From this heterochromatin gene panel, a weighted score 248 was calculated for each sample in the PDX and clinical cohorts following a similar strategy 249 utilized in recent studies (10, 11, 18) . Notably, similar to NEPC samples having a distinctly 250 higher NE score compared to adenocarcinomas, NEPC samples also have a significantly 251 higher heterochromatin score compared to adenocarcinoma (Fig. 1H) . Importantly, the 252 heterogeneity among PDX samples is much smaller than that observed in any clinical 253 cohorts regardless of the scoring system employed, further demonstrating that our PDX 254 collection both clearly reflects the clinical features of NEPC and adenocarcinoma and 255 provide a distinct system to study PCa subtypes. Together, these analyses indicate that a 256 heterochromatin-related gene expression signature is a unique feature of NEPC tumors. 257 258
Expression of heterochromatin protein 1α (HP1α) is upregulated early and steadily 259 during NEPC development 260
Inspired by the critical functional role of heterochromatin structure in modulating cell 261 behavior and gene expression (6,7), we hypothesized that these NEPC-specific 262 heterochromatin signature genes could contribute to NEPC development. As such, we 263
Research. attempted to identify a potential NEPC driver gene from our 36 heterochromatin signature 264 genes. In addition to a final upregulation in terminal NEPC, expression of the candidate 265 driver gene would also be increased early prior to full NEPC development. We thus analyzed 266 the RNA-seq profile of the LTL331/331R NE-transdifferentiation model with samples from 267 castration-induced dormant time points prior to full NEPC relapse (21, 22) . Ranked by the 268 gene expression difference between pre-and post-castration samples, elevated expression 269 of HP1α was found to be an early and dramatic event occurring upon host castration. 270
Conversely, expression of other genes that have been reported to be associated with NEPC 271 such as EZH2 and CBX2 (9,23) were only upregulated in the fully developed NEPC sample 272 (LTL331R) (Fig. 2A) . Interestingly, we also noticed that Hp1α expression gradually increased 273 as the NE phenotype progressed from partial to more dominantly overt in the Pten/Tp53 274 CRPC mouse model (Fig. S2A) , lending further support that elevated HP1α expression is an 275 early event in NEPC development. 276
To validate our findings, we performed quantitative RT-PCR (qRT-PCR) to detect 277 HP1α expression at the mRNA level and IHC staining and Western blotting to detect HP1α 278 expression at the protein level in our PDX collection. Both the mRNA and protein levels of 279
HP1α are significantly increased in NEPC PDXs (Fig. 2B-2D, S2B ). Furthermore, we 280 confirmed HP1α expression in the LTL331/331R castration time-series samples. Consistent 281 with the RNA-seq data, both the mRNA and protein expression of HP1α increased upon host 282 castration, with increased mRNA observed as early as 1 week post-castration and elevated 283 protein expression observed 3 weeks post-castration ( Fig. 2E-2G ). Taken together, these 284
Research. NEPCs (n=6) compared to adenocarcinomas (n=30) (Fig. 3A) (23). In the Beltran et al. 2016 293 cohort, HP1α expression was also significantly upregulated in NEPCs (n=15) compared to 294 CRPC adenocarcinoma samples (n=34) by around two folds (Fig. 3B) (10) . In another cohort 295 consisting of 35 metastatic CRPC samples, 4 samples with NEPC features expressed 296 significantly higher HP1α mRNA than other typical adenocarcinomas (Fig. 3C) (Fig. 3D, 3E) . These data together demonstrate that HP1α is highly expressed in 304
NEPC. 305
Research. While HP1α is dramatically upregulated in NEPC, we also noticed that some 306 adenocarcinomas also expressed higher levels of HP1α than others (Fig. 3D) . We then 307 investigated whether the expression of HP1α is associated with poor patient prognosis, thus 308 possibly being a pre-disposing factor to poor outcome. Among the 103 primary 309 adenocarcinoma samples in the VPC cohort, there were 37 samples with clinical follow-up 310 information. Kaplan-Meier analysis showed that patients with high expression of HP1α (IHC 311 score>=2) had a significantly shorter disease-free survival time (HR=4.627, p=0.0074) than 312 low HP1α-expressing patients (IHC score <2) (Fig. 3F) . For CRPC patients, the group with 313 high expression of HP1α (top 1/3) had a significantly shorter overall survival time after the 314 first hormonal therapy (HR=2.961, p=0.021), implying that HP1α positively correlates with 315 poor prognosis upon hormonal therapy (Fig. 3G) . Overall, these analyses indicate that 316 increased expression of HP1α is a poor prognostic factor in advanced PCa. 317
318
HP1α knockdown inhibits NEPC cell proliferation and induces apoptosis, leading to 319 tumor growth arrest 320
Considering that HP1α is significantly upregulated in NEPC, we proceeded to 321 investigate its function in NEPC cells. NCI-H660 is a unique and typical NEPC cell line (30). 322
Consistent with the high HP1α expression observed in clinical NEPC samples, HP1α is also 323 expressed at the highest level in H660 cells compared to seven other PCa cell lines at both 324 RNA and protein levels (Fig. S3A) . We thus constructed stable H660 cell lines with HP1α 325 knocked down using lentiviral-delivered shRNAs (Fig. 4A) overall proliferation of H660 cells was significantly inhibited, as evaluated by both crystal 327 violet staining and cell counting (Fig. 4B, S3B) . We further performed colony formation 328 assays to evaluate the reproductive and survival ability of single cells. Remarkably, HP1α 329 knockdown was able to ablate the colony formation ability of H660 cells (Fig. 4C) . We then 330 proceeded to analyze in greater detail the potential cellular mechanisms underlying the 331 attenuation of cell growth mediated by HP1α knockdown. An EdU incorporation assay 332
showed that knockdown of HP1α led to a significant reduction of EdU-positive, DNA 333 synthesis-active cells (Fig. 4D) . Furthermore, an apoptosis assay and FACS analysis 334 indicated that HP1α knockdown also promoted cell early-apoptosis and final death (Fig. 4E,  335 4F). Molecularly, the apoptosis markers cleaved-caspase 3 and cleaved-PARP1 were both 336 upregulated in knockdown cells (Fig. 4G) ; multiple machineries involved in DNA damage 337 repair and cell cycle progression were also impaired in HP1α knockdown cells as 338 determined by GSEA and ingenuity pathway analysis (IPA) from stable cell line 339 transcriptomic profiles (Fig. 4H, S3C, S3D ). Thus, HP1α depletion inhibited NEPC cell 340 proliferation and induced apoptosis in vitro. 341
We then assessed the functional impact of HP1α knockdown on tumor growth in vivo. 342
Compared to control H660 cells, xenograft tumor growth of the KD2 stable cell line with 70% 343
HP1α knockdown (Fig. 4A, S3E ) was observed to be dramatically inhibited and much slower, 344 as determined by continuous tumor volume measurements and final fresh tumor weights 345 (Fig. 4I, 4J) (Fig. 5A) . Upon ADT using 357 charcoal-stripped serum (CSS) or enzalutamide (EnZ) treatment for 14 days, both control 358 and HP1α-overexpressing V16D cells were assessed for the expression of terminal NE 359 markers. HP1α overexpression significantly promoted the expression of NCAM1 (CD56) and 360 NSE, as shown by both qRT-PCR and Western blotting (Fig. 5B, 5C ). HP1α overexpression 361 alone was not able to induce NE transdifferentiation (Fig. 5B, 
5C). Further transcriptomic 362 analysis of control and HP1α-overexpressing V16D cells upon EnZ treatment revealed that 363
HP1α overexpression consistently upregulated the expression of a panel of NEPC marker 364 genes and enriched neuronal-associated signaling pathways (Fig. 5D, 5E (10, 24, 25, 27) (Fig. 5F, 5G, S4B, S4C) . Overall, these analyses suggest that HP1α is a 370 potential functional driver promoting NE transdifferentiation. 371 372
HP1α represses AR and REST expression and enriches H3K9me3 on their promoters 373
We further analyzed how HP1α contributed to the NE phenotype. A major function of 374 HP1α in heterochromatin is to repress gene expression using epigenetic machineries 375 (31,32), which is an observation supported by our transcriptomic analyses with HP1α 376 knockdown and overexpressing cells (Fig. 5E, S4D) . Decreased or loss of expression of the 377 crucial adenocarcinoma lineage-specific transcription factors AR, FOXA1 and REST is a 378 well-established mechanism leading to NE differentiation (12) (13) (14) . Notably, when HP1α was 379 overexpressed in V16D cells, AR and REST were downregulated at both the mRNA and 380 protein levels (Fig. 6A, 6B, S5A ). Consistently, a panel of AR target genes that are 381 repressed in clinical NEPCs are also downregulated upon HP1α overexpression in V16D 382 cells (Fig. 6C) . Reciprocally, HP1α knockdown in H660 cells reactivated AR and REST 383 mRNA expression (Fig. S5B) DOI: 10.1158/0008-5472.CAN-17-3677 ( Fig.6D, S5C-S5E ). Pericentric heterochromatin is a constitutive heterochromatin structure 390 characterized by the repressive histone mark H3K9me3 (32). We then performed a 391 chromatin immunoprecipitation (ChIP) assay to examine the occupancy of H3K9me3 on the 392 promoter regions of AR and REST following HP1α modulation. Interestingly, in V16D cells, 393
HP1α overexpression increased the occupancy of H3K9me3 on both the AR and REST 394 promoters, while its knockdown in H660 cells decreased H3K9me3 enrichment on the AR 395 promoter (Fig. 6E, S5F ). In accordance with our findings in cell lines, the pericentric 396 heterochromatin geneset is consistently and significantly enriched in NEPCs compared to 397 adenocarcinomas in our PDX models, multiple clinical cohorts, and GEM models (Fig. 6F,  398 
S5G). Meanwhile, Pearson correlation analyses with multiple clinical cohorts showed that 399
HP1α expression is negatively correlated with AR and REST expression in advanced PCa 400 samples (Fig. 6G, 6H, S5H) (10, 24, 25, 27) . Overall, our data indicate that HP1α could 401 regulate expression of the two crucial adenocarcinoma lineage-specific transcription factors 402 AR and REST potentially via modulating the enrichment of H3K9me3 on their promoters. Author Manuscript Published OnlineFirst on DOI: 10.1158/0008-5472.CAN-17-3677 model, and also mirrors the clinical progression of NEPC where most cases appear after 447 hormonal therapy (3, 33) . In terminal NEPC cells where HP1α mainly functions as a regulator 448 of aggressiveness, HP1α knockdown cannot alter NE phenotype (Fig. S6A) heterochromatin genes in NEPCs may also explain the highly proliferative feature of NEPC, 469 for which HP1α may play a driver function. Another potential mechanism underlying the 470 essential function of HP1α in NEPC aggressiveness is that HP1α depletion impaired DNA 471 damage response (DDR) machineries, which is in accordance with previous studies (46, 47) . 472
Most recently, another study also reported that a DDR pathway is enriched in NEPC, 473 contributing to NEPC cell proliferation (48). Overall, HP1α could potentially serve as a 474 therapeutic target for effective management of developed NEPC. 475
Our findings also suggest a novel, HP1α-mediated mechanism of NEPC 476 development. AR, FOXA1 and REST are the three crucial adenocarcinoma lineage-specific 477 transcription factors maintaining luminal epithelial characteristics (12) (13) (14) . Our data 478 demonstrates that HP1α can repress AR and REST expression in adenocarcinoma cells, 479 while its depletion in NEPC cell can reactivate their expression. HP1α gene was first 480 identified to be a modulator of position effect variegation where euchromatic genes 481 abnormally juxtaposed with pericentric heterochromatin could be silenced due to compaction 482 into heterochromatin (49). In our study, we also found that HP1α may play an epistatic role 483 in regulating the pericentric heterochromatin apparatus. The repressive histone mark 484
H3K9me3 is a hallmark of pericentric heterochromatin and also a major substrate 485 recognized by HP1α (31, 32) . Given that the AR and REST genes are natively located in the 486 vicinity of pericentric heterochromatins (Xq12 and 4q12 respectively, Fig. S6C Alternative splicing has been suggested to suppress REST in NEPCs (16). HP1α was also 498 reported to mediate mRNA alternative splicing and exon recognition (50). As such, HP1α 499 might be involved in mediating REST splicing as well. Our data here suggests 500
HP1α/H3K9me3 as a new mechanism leading to the silencing of REST mRNA in most 501 NEPC samples. 502
In summary, our data imply a novel mechanism underlying NEPC development: 503 HP1α drives the abnormal formation of pericentric heterochromatin, which in turn promotes 504 ADT-induced NE transdifferentiation via repressing AR and REST expression, and confers 505 the malignant NEPC phenotype via promoting aggressive proliferation and cell survival. 506
Taken together HP1α can be considered an early and master mediator of NEPC 507 development and aggressiveness, making it an exceptional novel therapeutic target for 508 potentially effective treatment of NEPC. calculated based on the gene panels from Beltran et al. 2016 (10) and Lee et al. 2016 (18) . 685
Heterochromatin scores were calculated based on the weighted gene panel from (G) . 686
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